Immunohistochemical analysis of estrogen receptors in 938 breast carcinomas: Concordance with biochemical assay and prognostic significance

Applied Immunohistochemistry

Volumn 3, Issue 4, 1995, Pages 222-231

  de Mascarel, I ^a   Soubeyran, I ^a   Macgrogan, G ^a   Wafflart, J ^a   Bonichon, F ^a   Durand, M ^a   Avril, A ^a   Mauriac, L ^a   Trojani, M ^a   Coindre, J M ^a,b  

^a INSTITUT BERGONIÉ   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Biochemical assay; Breast carcinoma; Concordance; Estrogen receptors; Immunohistochemical analysis; Prognostic significance

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BIOASSAY; BREAST CARCINOMA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0028868974     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Mauriac L. Durand M. Chauvergne J. David M. Wafflart J. Les cancers du sein à haut risque métaslatique: prédiction de la survic par les récepfeurs stéroidiens. Bull Cancer 1989: 76:33–41.
2. Mauriac L. Wafflart J. Trojani M. Durand M. Les cancersdu sein inflammatoires: corrélation entre anatomopathologie et dosage des réccpteurs stéroïdiens. Bull Cancer 1983:70: 160–4.
3. Soubeyran I. Coindre JM. Wafflart J. et al. Immunohisto-chemical determination of pS2 in invasive breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995; 34:119–28.
4. Al Saati T. Clamens S. Cohen-Knafo E, et al. Production of monoclonal antibodies to human estrogen-receptor protein (ER) using recombinant ER (RER). Int J Cancer 1993;55: 651–4.
5. Soubeyran I. Quenel N. Intéréts de limmunohistochimie dans l’évaluation de la réponse á l’hormonothérapie néoadjuvante des cancers du sein. Thèse de Médecine n° 3106, Université de Bordeaux II, 1993.
6. Battifora H. Mehta P. Ahn C. Esteban JM. Estrogen receptor immunohistochemical assay in paraffin-embedded tissue. A better gold standard? Appl Immunochem 1993;1:36–45.
7. Pertschuk LP. Kim DS. Nayer K, et al. Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Cancer 1990;66:1663–70.
8. Gilbert L. Elwood LJ. Merino M. et al. A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J Clin Oncol 1993:11: 49–58.
9. Hurlimann J. Gebhard S. Gomez F. Estrogen receptor, progesterone receptor. pS2, ERD5, HSP27, and cathepsin D in invasive ductal breast carcinomas. Hislopathology 1993:23: 239–48.
10. Querzoli P Ferretti S Marzola A. et al. Clinical usefulness of estrogen receptor immunocytochemistry in human breast cancer. Tuinori 1992:78:287–90.
11. Tesch M. Shawwa A. Henderson R. Immunohistochemical determination of estrogen and progesterone receptor status in breast cancer. Am J Clin Palhol 1993:99:8–12.
12. Kaldjian EP. Jin L, Davenport RD, Lloyd RV. Immunohistochemical analysis of hormone receptors, tumor vascularity, and proliferative activity in paraffin-embedded sections of breast carcinoma tissues. Appl Immunohistochem 1993; 1:31–8.
13. Andersen J. Ørntoft T. Poulsen HS. Semi-quantitative oestrogen receptor assay in formalin-fixed paraffin sections of human breast cancer tissue using monoclonal antibodies. Br J Cancer 1986:53:691–4.
14. Soomro S. Shousha S. Sinnett HD. Oestrogen and progesterone receptor in screen-detected breast carcinoma: an immunohistochemical study using paraffin sections. Hislopathology 1992;21:543–7.
15. Allred DC. Bustamante MA. Daniel GO. Gaskill HV. Cruz AA. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Arch Surg 1990:125:107–13.
16. Reiner A. Neumeister B. Spona J. Reiner G. Schemper M. Jakesz R. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 1990:50:7057–61.
17. Andersen J. Thorpe SM. King WJ., et al. The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays. Eur J Cancer 1990:26:442–9.
18. Pari FF. Posey YF. Discrepancies of the biochemical and immunohistochemical estrogen receptor assays in breast cancer. Hum Pathol 1988:19:960–6.
19. Walker KJ, Bouzubar N, Robertson J. et al. Immunocytochemical localisation of estrogen receptor in human breast tissue. Cancer Res 1988:48:6517–22.
20. Robertson JFR, Bates K, Pearson D, Blarney RW, Nicholson RI. Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer 1992:65:727–30.
21. Press MR. Schwartz AM. Prognostic markers in breast cancer: laboratory analysis of breast biopsies. San Francisco. CA: United States and Canadian Academy of Pathology. 1994.
22. Mauri FA. Veronese S. Frigo B, et al. ER1D5 and H222 (ER-1CA) antibodies to human estrogen receptor protein in breast carcinomas. Results of multicentric comparative study. Appl Immunochem 1994;2:157–63.
23. Battifora H, Mehta P. Ahn C, Esteban JM. Immunocytochemistry of hormone receptors in routinely processed tissues. Appl Immunohistochem 1994;2:143–5.
24. Cowen PN, Teasdale J. Jackson P, Reid BJ. Oestrogen receptor in breast cancer: prognostic studies using a new immunohistochemical assay. Histopathology 1990:17:319–25.
25. Lacombe MJ, Delarue JC, Mouriesse H. et al. Human breast tumors: a comparison between the biochemical method of measuring estrogen and progesterone receptors and that of an immunohistochemical method. Gvnecol Oncol 1989;32: 174–9.
26. Snead J. Bell JA. Dixon AR, et al. Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin-fixed, paraffin-embedded tissue: a comparison with frozen section methodologv. Histopathology 1993:23:233–8.
27. Charpin C, Martin PM, Jacquemier J, et al. Estrogen receptor immunocytochemical assay (ER-ICA): computerized image analysis system, immunoelectron microscopy, and comparisons with estradiol binding assays in 115 breast carcinomas. Cancer Res (suppl) 1986;46:4271s-7s.
28. El-Badawy N, Cohen C, De Rose PB, Sgoutas D. Immunohistochemical estrogen receptor assay: quantitation by image analysis. Mod Palhol 1991:4:305–9.
29. Charpin C, Martin PM, De Victor B. et al. Multiparametric study (SAMBA 200) of estrogen receptor immunocytochemical assay in 400 human breast carcinomas: analysis of estrogen receptor distribution heterogeneity in tissues and correlations with dextran-coated charcoal assays and morphological data. Cancer Res 1988:48:1578–86.
30. Esteban J, Battifora H, Warsi Z, Bailey A, Bacus S. Quantification of estrogen receptors on paraffin-embedded tumors by image analysis. Mod Pathol 1991:4:53–7.
31. lino Y. Sugamata N. Maemura M. et al. Intersite variation of estrogen receptors in human breast cancers and response to endocrine therapy. Oncology 1992:49:89–92.
32. Shousha S, Stamp T, James KR, Alaghband-Zadeh J. Immunohistological study of oestrogen receptors in breast carcinomas that are biochemically receptor-negative. J Clin Pathol 1990:43:239–42.
33. Jacquemier J. Gandilhon PH. Charpin C. et al. Tissu mammaire: récepteurs estrogéniques. Analyse immunohistochimique et biochimique du tissu normal, hyperplasique et du carcinome in situ. A propos de 86 cas. Bull Cancer 1987; 74:129–49.
34. Markopoulos C. Berger UTA. Wilson P. Gazet JC. Coombes RC. Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. Br Med J 1988:296:1349.
35. Netto J. Cheek JH. Zachariah NY, et al. Steroid receptors in benign mastectomy tissue. Am J Clin Pathol 1990:94:14–7.
36. Khan SA. Rogexs MA. Obando JA. Tamsen A. Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 1994;54:993–7.
37. Lee KC. Chan JKC. 1D5: a superior anti-estrogen receptor antibody reactive in routine paraffine sections. Adv Anat Pathol 1994:1:52–5.
38. Balaton AJ. Interpretation of estrogen receptor immuno-staining. Point of view. In: Advances of anatomic pathology. New York: Raven Press. 1995:69–70.
39. Mac Grogan G. Bonichon F. de Mascarel I. et al. Prognostic value of P53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Br Cancer Res Treat 1995:36:71–81.
40. Winstanley J. Cooke T. Murray GG. et al. The long-term prognostic significance of oestrogen receptor analysis in early carcinoma of the breast. Br J Cancer 1991:64:99–101.
41. Andry G, Suciu S, Pratola D, et al. Relation between estrogen receptor concentration and clinical and histological factors: their relative prognostic importance after radical mastectomy for primary breast cancer. Eur J Cancer Clin Oncol 1989:25:319–29.
42. Spyratos F. Hacene K. Tubiana-Hulin M. Pallud C. Brunet M. Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. Eur J Cancer Clin Oncol 1989:25:1233–40.
43. Nomura Y, Miura S, Koyama H. et al. Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer. Cancer 1992;69:153–64.
44. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic. or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 1992;339:1–15. 71–85.
45. Katz RL. Patel S. Sneige N. et al. Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinomas. Breast Cancer Res Treat 1990:15:191–203.
46. Shek LL. Godolphin W. Survival with breast cancer: the importance of estrogen receptor quantity. Eur J Caneer Clin Oncol 1989;25:243–50.
47. Esteban JM. Ahn C. Mehta P. Battifora H. Biological significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer patients. Am J Clin Pathol 1994;102:S9-S12.